TauRx seeks UK MHRA approval for revolutionary Alzheimer's treatment
TauRx seeks UK approval for HMTM to treat Alzheimer's, marking a significant milestone in treatment.
TauRx Pharmaceuticals has applied to the UK Medicines and
Healthcare Products Regulatory Agency for approval of hydromethylthionine
mesylate (HMTM) to treat Alzheimer's disease. The treatment targets mild
cognitive impairment and mild to moderate dementia caused by Alzheimer's.
Commenting on the submission, Professor Claude Wischik,
Executive Chairman of TauRx, said: “This is a significant milestone for TauRx
and is an important step in potentially bringing a new type of treatment and a
new hope to patients and families who carry the burden of this terrible
disease.”
Previously, the UK regulator had assigned HMTM to the
innovative licensing and access pathway. If approved, the UK could be the first
country to provide this oral treatment.
The marketing application is supported by extensive evidence
from the 24-month Phase III LUCIDITY clinical trial and two earlier Phase III
studies, all showing HMTM's effectiveness in slowing cognitive decline,
preserving daily functioning, and reducing brain atrophy.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Discussion